Coldstream Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Coldstream Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$396K	Sell	2,084 -180	-8%	-$30.9K	0.01%	840
2026 Q1	$382K	Buy	2,264 +703	+45%	+$120K	﹤0.01%	840
2025 Q4	$263K	Buy	+1,561	New	+$254K	﹤0.01%	970
2025 Q2	–	Sell	-524	Closed	-$67K	–	2124
2025 Q1	$67K	Buy	+524	New	+$71.1K	﹤0.01%	1548
2023 Q2	–	Sell	-4,258	Closed	-$550K	–	842
2023 Q1	$550K	Sell	4,258 -1,821	-30%	-$238K	0.02%	407
2022 Q4	$798K	Buy	+6,079	New	+$786K	0.03%	302
2022 Q2	$783K	Buy	+6,654	New	+$790K	0.03%	273
2017 Q4	–	Sell	-2,142	Closed	-$238K	–	321
2017 Q3	$238K	Buy	+2,142	New	+$229K	0.03%	265

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Coldstream Capital Management's IBB Position: Q2 2026 in Review

Coldstream Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 8% in Q2 2026, selling an estimated $30.9K and leaving 2,084 shares worth $396K. The position accounts for 0.01% of the portfolio, ranked #840.

Coldstream Capital Management first reported a position in IBB in Q3 2017 and has held it in 8 quarters since. The position peaked at $798K in Q4 2022. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Coldstream Capital Management held 2,084 shares of iShares Biotechnology ETF worth $396K as of Q2 2026.
Coldstream Capital Management sold 180 iShares Biotechnology ETF shares in Q2 2026, an estimated $30.9K.
iShares Biotechnology ETF made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #840 holding.
Coldstream Capital Management first reported a position in iShares Biotechnology ETF in Q3 2017 and has held it in 8 quarters since.
Coldstream Capital Management's iShares Biotechnology ETF position peaked at $798K in Q4 2022.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.